Study guide
3.3 Osteoporosis Drug Therapy: Antiresorptive, Anabolic, and Hormonal Agents
ARRT Bone Densitometry Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Orientation & the ARRT Blueprint
1.1 About the ARRT Bone Densitometry Examination 1.2 Eligibility, Structured Education, and Clinical Experience
2 Chapter 2: Osteoporosis, Bone Biology & Risk Factors
2.1 Osteoporosis: Definitions, Types, and WHO Diagnostic Criteria 2.2 Bone Functions, Structural Anatomy, and Bone Types 2.3 Bone Cells, the Remodeling Cycle, and Calcium Homeostasis 2.4 Risk Factors, Secondary Causes, and Bone-Compromising Medications
3 Chapter 3: Indications, Prevention & Treatment
3.1 The Bone Mass Measurement Act: Covered Indications and Coding 3.2 Prevention: Nutrition, Exercise, Smoking Cessation, and Fall Prevention 3.3 Osteoporosis Drug Therapy: Antiresorptive, Anabolic, and Hormonal Agents
4 Chapter 4: Patient Preparation, Support & Radiation Safety
4.1 Patient Support, Disabilities, Ergonomics, and Transfer Techniques 4.2 Patient Instructions: Explaining the Exam, Dose, Duration, and Motion Control 4.3 Patient History, Contraindications, and Pregnancy Screening 4.4 Scan Preparation: Patient Data Entry, Artifact Removal, and Infection Control 4.5 Radiation Safety in DXA: ALARA, Distance, and Dose Levels
5 Chapter 5: DXA Physics & Instrumentation
5.1 Physical Principles of Dual-Energy X-ray Absorptiometry 5.2 Beam Geometries: Pencil Beam and Fan Beam Systems 5.3 Fan-Beam Geometry: Source–Object–Detector Distances, Magnification, and Centering 5.4 The Scan Analysis Algorithm: Soft Tissue, Bone Edge Detection, BMC, Area, and BMD
6 Chapter 6: Measuring & Reporting Bone Mineral Density
6.1 Statistics for Densitometry: Mean, Standard Deviation, and Coefficient of Variation 6.2 T-Scores, Z-Scores, and Reference Database Selection 6.3 Clinical Indications for BMD Testing and the FRAX Tool 6.4 Vertebral Fracture Assessment and Trabecular Bone Score 6.5 Whole Body DXA, Body Composition, and Pediatric Scanning
7 Chapter 7: Quality Control, Precision & Equipment Management
7.1 Accuracy, Precision, and the Sources of Precision Error 7.2 Daily Quality Control, Phantoms, and Control Charts 7.3 In Vivo Precision Studies and RMS-SD Calculation 7.4 Determining and Applying the Least Significant Change 7.5 Maintenance, Repair, Relocation, Cross-Calibration, and Software Upgrades
8 Chapter 8: DXA Informatics & Data Management
8.1 DXA Informatics, DICOM, PACS, and Data Management
9 Chapter 9: Lumbar Spine DXA
9.1 Lumbar Spine Anatomy, Landmarks, and Regions of Interest 9.2 Lumbar Spine Scan Acquisition and ROI Edge Placement 9.3 Lumbar Spine: Compensating for Body Habitus, Variant Anatomy, Pathology, and Low Bone Density 9.4 Lumbar Spine Positioning: The Leg Block, Centering, and Common Challenges 9.5 Lumbar Spine Problems: Poor Bone Edge Detection and Obscured Intervertebral Spaces 9.6 Lumbar Spine: Variant Anatomy, Fractures, Degenerative Pathology, Calcification, and Surgery 9.7 Lumbar Spine Analysis: Vertebral Exclusion and Reporting Rules 9.8 Lumbar Spine Follow-Up Scans and Rate of Change
10 Chapter 10: Proximal Femur DXA
10.1 Proximal Femur Anatomy, Landmarks, and Regions of Interest 10.2 Femur Selection: Right, Left, and Dual Femur Scanning 10.3 Proximal Femur Scan Parameters and Compensation 10.4 Proximal Femur Positioning: Neck Rotation, Shaft Placement, and Positioning Aids 10.5 Proximal Femur Problems: Ischium, Short Neck, Arthritis, Fracture, and Hardware 10.6 Femoral ROI Analysis: Femoral Neck, Total Hip, and Ward's Area 10.7 Proximal Femur Follow-Up Scans and Rate of Change
11 Chapter 11: Forearm DXA
11.1 Forearm Anatomy, Landmarks, and Adjacent Structures 11.2 Forearm Indications and Side Selection 11.3 Forearm Length Measurement, Scan Parameters, and Positioning 11.4 Forearm Regions of Interest: One-Third, Mid, Ultradistal, and Total 11.5 Forearm Problems: Edge Detection, Artifacts, Low Bone Density, and Joint Disease 11.6 Scan Analysis: Region Placement, Window Level, and Reported Values 11.7 Forearm Follow-Up Scans and Rate of Change
12 Chapter 12: Cross-Site Artifacts & Clinical Integration
12.1 Recognition, Impact, and Management of DXA Artifacts 12.2 Clinical Interpretation, Serial Comparison, and Reporting
3.3 Osteoporosis Drug Therapy: Antiresorptive, Anabolic, and Hormonal Agents
Key Takeaways Explain This Topic AI
Antiresorptive agents include bisphosphonates such as alendronate, risedronate, ibandronate, and zoledronic acid, plus the RANK ligand inhibitor denosumab.
Bone-formation (anabolic) agents include teriparatide and abaloparatide, which are parathyroid hormone pathway analogs, and romosozumab, a sclerostin inhibitor with dual action.
Hormonal and related agents include estrogen therapy, the selective estrogen receptor modulator raloxifene, and calcitonin.
Denosumab must not simply be stopped: discontinuation causes rapid rebound bone loss and multiple vertebral fractures unless followed by an antiresorptive agent.
Antiresorptive therapy typically raises spine BMD by 2% to 4% in the first year, while anabolic agents produce larger spine gains, which is why serial comparison must use absolute BMD against the facility least significant change.
Last updated: September 2026
3.3 Osteoporosis Drug Therapy: Antiresorptive, Anabolic, and Hormonal Agents
Quick Answer: ARRT groups osteoporosis drug therapy into antiresorptive , formation (anabolic) , and hormonal and others . Antiresorptives — bisphosphonates and denosumab — slow osteoclastic resorption and raise spine BMD roughly 2–4% in the first year. Anabolics — teriparatide, abaloparatide, romosozumab — stimulate formation and produce larger spine gains. Hormonal agents include estrogen therapy, the SERM raloxifene, and calcitonin. Technologists do not prescribe, but they must recognize what each class does to a serial BMD trajectory.
Why Drug Class Matters at the Scanner
Serial DXA interpretation is drug-aware. A 1.5% spine gain after a year of alendronate is an expected therapeutic response that may still fall below the facility least significant change. The same 1.5% after a year of teriparatide is an underperformance worth flagging. And a patient whose denosumab lapsed eight months ago may present with a spine BMD that has fallen below her pre-treatment baseline — a pattern that looks like a technical error and is not. Knowing the class tells you whether the number is plausible.
Antiresorptive Agents
Antiresorptives reduce the number and activity of osteoclasts. Remodeling slows, the remodeling space fills in, existing bone mineralizes more completely, and BMD rises for one to several years before plateauing.
Bisphosphonates
Bisphosphonates bind avidly to hydroxyapatite at sites of active remodeling and are internalized by osteoclasts, disrupting their function and survival. They persist in bone for years, which is the basis of the drug holiday concept.
- Agent Common routes and intervals
- Alendronate Oral daily or weekly
- Risedronate Oral daily, weekly, or monthly
- Ibandronate Oral monthly or intravenous quarterly
- Zoledronic acid Intravenous once yearly
Oral administration rules patients ask about constantly: take first thing in the morning on an empty stomach with a full glass of plain water , remain upright and take nothing else by mouth for at least 30 minutes (60 for ibandronate). The rules exist because oral bioavailability is under 1% and is abolished by food, coffee, juice, and — notably — calcium supplements, and because reclining risks pill esophagitis.
Drug holidays. Because bisphosphonate persists in the skeleton, patients at lower ongoing risk may pause therapy after roughly 5 years of oral or 3 years of intravenous treatment, with periodic reassessment. During a holiday, DXA monitoring is what detects resumption of loss. Denosumab has no comparable holiday.
Atypical femoral fracture and osteonecrosis of the jaw are rare long-duration adverse effects. Their relevance to densitometry is that many DXA protocols now include a long femur view to screen for the lateral cortical thickening or beaking that precedes atypical fracture in long-term users.
Denosumab
Denosumab is a monoclonal antibody against RANK ligand (RANKL) . By binding RANKL it prevents osteoclast formation, function, and survival — the same pathway estrogen protects. It is given as a subcutaneous injection every 6 months .
The densitometrically critical fact: denosumab is not retained in bone . When it is stopped or delayed, the suppressed remodeling rebounds sharply, producing rapid BMD loss back toward or below baseline and a documented risk of multiple vertebral fractures . Guidance is unambiguous that denosumab must not simply be discontinued; patients are transitioned to a bisphosphonate. If a patient reports a lapsed or long-delayed injection, that history belongs in the scan record because it explains an otherwise inexplicable decline.
Bone-Formation (Anabolic) Agents
Anabolic agents increase osteoblast number and activity, building new bone rather than preserving existing bone.
Agent Mechanism Administration
Teriparatide Recombinant human parathyroid hormone fragment PTH(1–34); intermittent daily exposure is anabolic whereas continuous elevation is resorptive Daily subcutaneous injection
Abaloparatide Analog of parathyroid hormone-related protein (PTHrP) Daily subcutaneous injection
Romosozumab Monoclonal antibody against sclerostin ; dual action increasing formation while decreasing resorption Monthly subcutaneous injection, 12 doses
Three points recur:
The PTH paradox. Continuously elevated endogenous PTH, as in primary hyperparathyroidism, causes cortical bone loss. Intermittent pulsed exposure, as with once-daily teriparatide, is anabolic. Same hormone, opposite skeletal effect, determined by exposure pattern.
Anabolic courses are time-limited and must be followed by an antiresorptive agent, or the gains are lost.
Sequence matters. Anabolic-then-antiresorptive produces greater BMD gains than the reverse; prior potent antiresorptive therapy blunts the response to a subsequent anabolic. Romosozumab carries a boxed warning regarding cardiovascular events and is avoided in patients with recent myocardial infarction or stroke.
Expect larger spine responses from anabolics — commonly in the range of 5% to 10% over one to two years — with more modest hip responses, because the spine is trabecular-rich and responds fastest.
Hormonal and Other Agents
Estrogen therapy (with progestin if the uterus is intact) prevents postmenopausal bone loss by restoring RANKL suppression. It is FDA-approved for prevention of postmenopausal osteoporosis and is generally used at the lowest effective dose for the shortest appropriate duration, with vasomotor symptoms as a common co-indication. Bone loss resumes when it stops.
Raloxifene , a selective estrogen receptor modulator (SERM) , is an estrogen agonist in bone and an antagonist in breast tissue. It reduces vertebral fracture risk and breast cancer risk; it has not demonstrated hip fracture reduction and raises venous thromboembolism risk.
Calcitonin , usually intranasal, inhibits osteoclasts weakly. Its BMD and fracture effects are modest and it is now a later-line option.
Calcium and vitamin D are adjuncts, not treatments. Every agent above was studied on a background of adequate calcium and vitamin D, and repletion is assumed rather than optional.
Summary Table for Serial Interpretation
Class Representative agents Expected first-year spine BMD trend
Bisphosphonate Alendronate, risedronate, ibandronate, zoledronic acid Increase of roughly 2–4%, then slower gains
- RANKL inhibitor Denosumab Steady increase that continues over years; rapid loss if stopped
- PTH pathway anabolic Teriparatide, abaloparatide Larger increase, commonly 5–10% over 1–2 years
- Sclerostin inhibitor Romosozumab Rapid large increase over a 12-month course
- SERM / estrogen Raloxifene, estrogen therapy Small increase or prevention of loss
- None (untreated postmenopausal) — Loss of roughly 1–2% per year
Against every one of these numbers stands the same rule: a measured change is reported as real only when it meets or exceeds the facility's least significant change, calculated from that technologist's own precision study.